BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 24, 2018
View Archived Issues
Local factors greatly affect myelination state
Read More
Pharmacokinetic data of anti-CD22 TTC BAY-1862864 suggest good stability and biodistribution
Read More
[225Ac]FPI-1434 demonstrates theranostic potential in multiple preclinical models of human cancer
Read More
Strong tumor-targeting in mice treated with the [99mTc]-labeled CCK2R-antagonist DGA1
Read More
Hisamitsu begins phase II trial in Japan with HP-5070 for primary local hyperhidrosis
Read More
ConsortiaTx signs license for foundational intellectual property related to CTX-944
Read More
Chromosome microarray reveals a chromosome 17q duplication and deletion in a patient
Read More
Weill Cornell Medicine describes improved CXCR4 ligands for PET imaging
Read More
Chengdu Euthare Therapeutics identifies CDK4 and CDK6 inhibitors
Read More
Raf kinase regulates mast cell activation, allergic response
Read More
Ocean University of China patents new antivirals
Read More
Japanese researchers present ROR-gammaT antagonists
Read More
CureVac begins phase I trial with prophylactic mRNA rabies vaccine CV-7202
Read More
Bayer synthesizes new CDK9 inhibitors
Read More
FDA approves Afluria Quadrivalent for use in individuals age 6 months and older
Read More
Plinabulin + Neulasta reduce grade 3/4 CIN and bone pain in phase II trial
Read More
Probiodrug discovers QPCT inhibitors
Read More
ADCT-602 studied in phase I/II trial for recurrent or refractory B-cell ALL
Read More
Darolutamide significantly extends metastasis-free survival in nonmetastatic CRPC
Read More
Celgene reports PFS improvement with Revlimid in smoldering multiple myeloma
Read More
Zymeworks and Leo Pharma enter licensing and research collaboration for bispecific antibodies
Read More
FDA agrees with Scynexis on phase III plans for ibrexafungerp in VVC
Read More
Enanta begins phase IIa study of EDP-938 to treat RSV infection
Read More
First positive phase III data for PIK3CA inhibitor alpelisib in breast cancer
Read More
Xortx's pre-IND meeting with FDA identifies accelerated clinical development plan for XRx-008
Read More
Santhera begins phase Ib/IIa study of POL-6014 in cystic fibrosis
Read More
Phase I study indicates lower effective dose with [18F]PSMA-11 than other PSMA ligands
Read More
Biogen discontinues development of vixotrigine for painful lumbosacral radiculopathy
Read More